Track the NEOGEN CORP share price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, NEOGEN CORP has recorded 126 reports. Market capitalisation: €1.3bn. The latest transaction was filed on 28 October 2025 (Levée d'options). Among the most active insiders: ADENT JOHN EDWARD. Every trade is free.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
25 of 126 declarations
Neogen Corp. (ticker: NEOG) is a U.S.-listed company traded on the NASDAQ, operating from Lansing, Michigan, United States. Founded in 1982 out of scientific work linked to Michigan State University, Neogen has grown from a small research-driven startup into a global specialist in food safety and animal safety. The company now serves customers in nearly 40 countries, with a commercial and operational footprint that spans North America, Europe, Latin America, and Asia-Pacific. ([neogen.com](https://www.neogen.com/about/)) Neogen’s business is organized around two core segments: Food Safety and Animal Safety. Food Safety includes solutions used to detect allergens, pathogens, microorganisms, and other contaminants, along with environmental monitoring, microbiology, and rapid testing tools for food processors and laboratories. Animal Safety covers immunoassay reagents and test kits, animal toxicology products, veterinary instruments and consumables, animal care and biosafety products, and genomics services for livestock and companion animals. Key brands include Petrifilm, Clean-Trace, Molecular Detection System, and Reveal. ([neogen.com](https://www.neogen.com/about/)) From a competitive standpoint, Neogen occupies a specialized niche in the intersection of diagnostics, biosafety, and quality assurance. Its model benefits from recurring consumables, a broad installed customer base, and rising regulatory demands across the food chain. The company’s customer set ranges from commercial labs to dairy, beef, poultry, and pork operators, reinforcing a relatively defensive demand profile tied to food-chain compliance rather than discretionary spending. ([neogen.com](https://www.neogen.com/about/)) Geographically, Neogen remains anchored in the United States, where its corporate headquarters are located at 620 Lesher Place in Lansing, Michigan. At the same time, it operates manufacturing, administrative, sales, and service sites across multiple regions, including Europe, Canada, Latin America, and Asia-Pacific. The company also notes manufacturing and distribution capabilities in locations such as the U.S., the Netherlands, the U.K., and other international markets, underscoring its global supply-chain reach. ([neogen.com](https://www.neogen.com/4ac3cb/globalassets/pdfs/quarterly-and-annual-forms/fy2025-q4-10k.pdf)) Recent corporate developments have centered on portfolio simplification and balance-sheet repair. Neogen completed the divestiture of its global Cleaners & Disinfectants business to Kersia Group in July 2025 for $130 million in cash at closing, with proceeds intended primarily for debt reduction. The company also completed a refinancing of its term loan and revolving credit facility in April 2025, lowering borrowing spreads and extending maturities. In the latest annual report, management highlighted ongoing integration work following the 3M Food Safety transaction, while fiscal 2025 revenue came in at $894.7 million and operating losses remained elevated, reflecting integration costs and restructuring actions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/711377/000095017025114388/neogen_fy25_annual_repor.pdf)) For francophone investors, NEOG is best viewed as a specialized U.S. healthcare-adjacent industrial technology company with attractive end-markets, but one that is still digesting a transformational acquisition and reshaping its portfolio. SEC Form 4 insider activity and governance disclosures remain relevant monitoring points for market participants following the turnaround. ([neogen.com](https://www.neogen.com/4ac3cb/globalassets/pdfs/quarterly-and-annual-forms/fy2025-q4-10k.pdf))